-
Scioto Biosciences, Inc. Announces First Patient Dosed in Phase Ib Study in Patients Diagnosed with Autistic Disorder
-
Scioto Biosciences Receives Series B Investment from Genome & Company
-
Scioto Biosciences and Abigail Wexner Research Institute at Nationwide Children’s Hospital Receive a $2.3 Million Dollar Phase II SBIR Grant to Develop Novel Therapy
Advancing Healing Through Microbiome Therapeutics
Scioto Biosciences is a clinical stage biotech company dedicated to innovative research and discovery in the field of microbiome therapeutics. Our team has developed a proprietary Activated Bacterial Therapeutics (ABT) platform for delivering best-in-class, live therapeutic bacteria to the gut. Our solution is focused on the activation of beneficial bacteria that have the potential to advance healing for various diseases associated with the GI tract, Oncology and CNS indications.
About Us